RETA: Gunggung utang perusahaan Reata Pharmaceuticals, Inc.

This price chart for Reata Pharmaceuticals (RETA) debt captures the indicator at 0.25. Reata Pharmaceuticals holds the status of the sole leader in Friedreich's ataxia therapy, granting the company complete pricing power. The business relies on the Skyclarys drug ecosystem, which creates a closed supply loop for specialized clinics. Development is accompanied by the implementation of software robots for data analysis and the automation of laboratory molecule screening.

This indicator consolidates short-term liabilities and long-term bonds, allowing investors to assess aggregate credit risk and balance sheet resilience against default. For Reata Pharmaceuticals (RETA), the acquisition by a major biotech behemoth eliminated the capital deficit, which is reflected in the absence of critical leverage and confirmed by the stable fluctuations of total debt on this chart.